John Simes

Position: Director
Group: Executive
Phone: Executive assistant: 9562 5002
Fax: 9565 1863
Location: Level 6
92-94 Parramatta Rd
Camperdown NSW 2050
Address: NHMRC Clinical Trials Centre
K25 - Medical Foundation Building
University of Sydney
NSW 2006 Australia


  • BSc (Med) (hons I), University of Sydney
  • MB BS (hons I), University of Sydney
  • SM (Master of Science in Biostatistics), Harvard University
  • MD 'Cancer clinical trials: statistical clinical and ethical issues', University of Sydney


Professor John Simes is Senior Principal Research Fellow and director of the CTC.

He is a leading international researcher in clinical trials, particularly in cancer, cardiovascular disease, diabetes and neonatal medicine. He co-leads the CTC's team of 150 who collaborate with clinical investigators and other researchers nationally and internationally in a research program aimed at improving health practice and health outcomes through better use of clinical trials research. He has  contributed to over 300 peer-reviewed articles, with many having a significant impact on current knowledge and clinical practice.

Professor Simes is the director of the Sydney Catalyst translational research centre, a virtual centre of cancer researchers in central Sydney and regional NSW. He is a founding member of the board of directors, Australian Clinical Trials Alliance (ACTA), formed in 2012 to promote effective and evidence based healthcare in Australia through investigator-initiated clinical trials.

He is a practising medical oncologist in neuro-oncology at Royal Prince Alfred Hospital and the Chris O'Brien Lifehouse and is professor of clinical epidemiology, Faculty of Medicine, University of Sydney. He has taught medical students and postgraduate students at the University of Sydney since 1989. He was awarded the Cancer Achievement Award for lifetime achievement in oncology by the Medical Oncology Group of Australia (2010) and the Distinguished Harvard Alum Award (Biostatistics) from Harvard University (2009) in recognition of his work in research. He has recently been elected as a Fellow of the Australian Academy of Health and Medical Sciences. He is a member of research committees, trials groups and boards, including cancer cooperative groups and safety and data monitoring committees.


Committee Memberships:

  • Australian Clinical Trials Alliance board
  • NHMRC CTC Research Committee
  • ANZ Clinical Trials Registry Advisory Committee
  • Management Committee, Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)
  • Management Committee and Executive, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
  • Joint coordinator, Cholesterol Treatment Trialists Collaboration (CTTC)
  • Steering Committee chair, International Trials of Aspirin to Prevent Recurrent Venous Thrombo-embolism (INSPIRE)
  • Safety and Data Monitoring Committee, Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
  • Scientific Advisory Committee, ANZ Breast Cancer Trials Group (ANZBCTG)
  • Scientific Advisory Committee, Australasian Gastro-Intestinal Trials Group (AGITG) (group coordinator since 2002)
  • Scientific Advisory Committee, Cooperative Trials Group for Neuro-Oncology (COGNO) (deputy chair)
  • Trial Management Committee, Sentinel Biopsy versus Axillary Clearance trial (SNAC)
  • Trial Management Committee, Aspirin to Prevent Recurrent Venous Thrombo-embolism (ASPIRE) (chair)
  • Trial Management Committee, Benefits Of Oxygen Saturation Targeting (BOOST II)
  • Trial Management Committee, Lactoferrin Infant Feeding Trial (LIFT)
  • Trial Management Committee, Individualised Molecular Pancreatic Cancer Therapy (IMPACT) (co-chair)

CV and publications:

Some recent publications

1. Simes J, Becattini C, Agnelli G, Eikelboom J, Kirby AC, Mister R, Prandoni P, Brighton TA, for the INSPIRE (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism) Study Investigators. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130(13): 1062-1071.

2. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Grazia Franzosi M, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet. Published online 9 Jan 2015.

3. Brighton T, Eikelboom J, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J, ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine 2012; 367(21): 1979-1987.

4. Sjoquist K, Burmeister B, Smithers B, Zalcberg J, Simes R, Barbour A, Gebski V, and for the Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology 2011; 12(7): 681-692.

5. Grimison PS, MR; Thomson, DB; Olver, IN; Harvey, VJ; Gebski, VJ; Lewis, CR; Levi, JA; Boyer, MJ; Gurney, H; Craft, P; Boland, AL; Simes, RJ; Toner, GC. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: updated analysis of a randomised trial. Journal of the National Cancer Institute 2010; 102(16): 1253-1262.

Link to further publications

Back to search results